- LEARNING CENTERS
- JOIN GRU
- Your GRU
- Log In
Latest prostate cancer research is turning its focus on the M0 space. M0 prostate cancer is a stage where the disease is non-metastatic but has become resistant to hormone therapy. Many therapeutic options for castration-resistant prostate cancer are approved and used for metastatic castration-resistant prostate cancer (mCRPC), but fewer options exist for those with non-metastatic (NM) CRPC.
Eric J. Small, MD, FASCO, defines nonmetastatic castration-resistant prostate cancer, or M0 disease. He then discusses the design, implementation, and results of the SPARTAN trial, which he presented at the 2018 Genitourinary Cancers Symposium. The study tested the efficacy of apalutamide in men with M0 disease.